
A federal judge in Boston ruled Thursday that the Trump administration cannot bar healthcare providers who receive certain federal HIV-treatment funds from acknowledging the gender identity of their transgender patients or from providing them gender-affirming care. U.S. District Judge William Young sided with national HIV medical associations and healthcare providers who had challenged new grant funding conditions attached to the Ryan White HIV/AIDS Program, a program Congress created in 1990 to provide medical care for low-income and uninsured people living with HIV.
According to Investing.com, which cited Reuters reporting, the ruling means providers receiving the funds cannot be blocked from acknowledging transgender patients’ gender identity or from providing them gender-affirming care. The outlet reported that beginning in March, the Health Resources and Services Administration, the HHS division that administers the program, added funding conditions meant to implement President Trump’s executive order directing the government to recognize only two sexes. Those new grant conditions required providers to ensure funded activities used sex-based definitions the administration described as grounded in biological reality, while avoiding what it called social or medical experimentation.
The lawsuit was filed in June by groups including the American Academy of HIV Medicine, the same report noted. Lambda Legal’s announcement of the case identified the full roster of plaintiffs as the American Academy of HIV Medicine, the HIV Medicine Association, the International Association of Providers of AIDS Care, and two provider plaintiffs, according to Lambda Legal.
What the Plaintiffs Argued
The plaintiffs contended the funding policy violated the Administrative Procedure Act, the federal law governing how agencies make, change, and repeal regulations, per the same Reuters account. They also argued the administration’s changes conflicted with the Ryan White Program’s statutory mandate to provide comprehensive medical services, and that the funding conditions discriminated based on transgender status while restricting doctors’ speech under the Constitution — pointing specifically to conditions that would prevent doctors from referring to patients by their preferred pronouns.
Central to the plaintiffs’ case was the claim that the Ryan White Program had historically included hormone therapy for transgender people, the report said. The dispute traces back to a broader executive order Trump signed in 2025 prohibiting federal funding for what he describes as gender ideology. The Kaiser Family Foundation has reported that the order directed agencies to take all necessary steps, as permitted by law, to end federal funding of what it calls gender ideology, according to KFF. KFF also found multiple reports of HIV programs and community health centers losing funding as a result of supporting programs inclusive of transgender people.
A Rejected Settlement and a Court Record
After a bench trial in September, Young urged the administration to settle the case, but the administration rejected the plaintiffs’ settlement proposal, according to an October 2 court filing cited by Investing.com. The case docket shows the court entered findings of fact, rulings of law, and an order for judgment on Thursday. It records the bench trial and final arguments as taking place on September 23, 2026, before the court took the matter under advisement.
The Ryan White statute itself, codified in Title 42 of the U.S. Code, directs the Secretary of Health and Human Services, acting through HRSA’s administrator, to make grants assisting with specified services in qualifying metropolitan areas — those that had a cumulative total of more than 2,000 reported and confirmed AIDS cases during the most recent five-calendar-year period for which data are available, per the U.S. Code.
Part of a Wider Pattern on Transgender Rights
Thursday’s ruling is not Young’s first clash with the administration over funding tied to LGBTQ+ Americans. In June 2025, Young ordered the National Institutes of Health to immediately restore research funds related to racial minorities and LGBTQ+ people, declaring the cuts illegal and void, according to POLITICO.
The HIV funding dispute unfolds against a backdrop of other administration actions affecting transgender Americans. Trump has banned transgender people from serving in the military and barred passport applicants from designating their gender identities, with the U.S. Supreme Court permitting both the military ban and the passport restriction to take effect. The administration has also moved to restrict gender-affirming care for transgender inmates in federal prisons and has backed state laws banning transgender athletes from female sports teams at public schools and universities. The HIV funding policy change came amid the administration’s broader push against transgender rights.









